Skip to main content
. 2018 Sep 11;17(16):1979–1991. doi: 10.1080/15384101.2018.1502573

Figure 2.

Figure 2.

Optimization of EdU-BrdU dual labeling technique applied to HSPC in-vivo A, Dual-deoxynucleoside labeling with single EdU (1.5 mg/mouse) and single BrdU dose (2 mg/mouse) separated by 2 hours (TI). Bone marrow cell were harvested 0.5 hours after BrdU administration. B, Dual-deoxynucleoside labeling with two doses of EdU (2 x 1.5 mg/mouse) and single dose of BrdU (2 mg/mouse). C, Representative dot-plots of LincKit+ cells and EdU/BrdU fractions frequency in three experimental settings. D, Ratio of S-phase exiting cells (EdU+BrdU) to S-phase entering cells (EdUBrdU+) in three experimental settings determined in LSK cells, LSK cells and their CMP, GMP and MEP subpopulations. Four to six mice were analyzed in each of the experimental settings. The experimentally obtained ratios were tested by Student’s t-test (one sample, two-tailed) to the expected theoretical ratio of 4.0 or 3.0 (see text). The ratios were significantly different (P < 0.05) from 4.0 in the left two columns. Results in the table are mean ± SEM.